SCHEMBL31401367

SCHEMBL31401367

CC(C)(C)OC(=O)N1CCC12CCNC2=O

nearest known ligand 0.41

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GRIN2B Q13224 1/20 0.41
GRIN2C Q14957 1/20 0.41
CCR5 P51681 2/20 0.38
MAPK1 P28482 1/20 0.36
USP2 O75604 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
BUB1 O43683 1/20 0.34
KDM4E B2RXH2 1/20 0.34
MAPT P10636 1/20 0.34
THRB P10828 1/20 0.34
DDB1 Q16531 1/20 0.34
CRBN Q96SW2 1/20 0.34
CCNC P24863 2/20 0.33
CDK8 P49336 2/20 0.33
NR1H2 P55055 3/20 0.32
RXRA P19793 2/20 0.32
NR1H3 Q13133 2/20 0.32
JAK3 P52333 1/20 0.32
KDM1A O60341 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2304050 0.92 GRIN2B (0.50) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL19852919 0.90 GRIN2B (0.46) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL9948870 0.89 GRIN2B (0.40) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL10167279 0.86 GRIN2B (0.50) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL21238736 0.86 GRIN2B (0.50) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL22975107 0.85 GRIN2B (0.46) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL21238799 0.85 GRIN2B (0.46) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL15936936 0.78 GRIN2B (0.51) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL24436783 0.78 GRIN2B (0.51) GRIN2BGRIN2CCCR5MAPK1USP2
SCHEMBL9948587 0.78 KDM4E (0.38) CCR5USP2KDM4EMAPTDDB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed